◈ Nootpedia
Compact view
Research pass: thorough Supplement · Capsule OPTIONAL-ADD MEDIUM

Acetyl-L-Carnitine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD MEDIUM

Real but mild "cleaner caffeine" energy + mitochondrial insurance for a 20yo athlete; the TMAO/cardiovascular concern (>30-fold rise on 1.5 g/day) is the only thing keeping it out of STRONG-CANDIDATE — cycling or stacking with TMAO-mitigating fiber/probiotics restores the case.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD

    The "cleaner caffeine" thesis is real for a meaningful subset of users; pairs well with already-locked V4 (citicoline, DHA, NAC). Low cost, low daily-burden. Caveat: TMAO concern is real, especially for someone optimizing for 60-year longevity. Cycle 8-12 weeks on / 4 off, or check plasma TMAO at 6 months and adjust. Run as 4-week trial; drop if no felt effect.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    Same upside; aging cognition starts to benefit more, mitochondrial function declines. TMAO concern still applies; cycle.

  • 50+, mild cognitive decline / MCI
    STRONG-CANDIDATE

    This is ALCAR's best evidence base. 1.5-3 g/day shows replicated benefit on cognitive scales. The TMAO trade-off is more favorable here because the cognitive benefit is established, dose is therapeutic, and time-horizon for atherosclerotic harm is shorter relative to immediate cognitive preservation value.

  • Anxiety-prone
    CAUTION

    Mild restlessness/overstimulation possible. Start at 250 mg AM; abandon if it amplifies anxiety. Stack with theanine.

  • High athletic load, tested status (WADA-tested competitor)
    OK

    not on WADA banned list as of 2026. Common in endurance/strength stacks; standard mitochondrial/recovery tool. ALCAR-specific performance benefit modest in healthy young athletes vs. carnitine-deficient older ones.

  • Sleep-disordered (insomnia, late chronotype)
    CAUTION

    Strict AM dosing only. Late chronotype people (like Dylan) should keep ALCAR before noon to avoid PM restlessness.

  • Recovery-focused (post-injury, post-illness)
    STRONG-CANDIDATE

    Mitochondrial substrate, neurotrophic support, peripheral nerve repair (artemin, NGF). Particularly relevant for nerve injuries (cubital tunnel, post-surgical, chemotherapy-induced).

  • Strength/anabolic-focused
    STANDARD TOOL

    Well-known in strength/bodybuilding stacks; supports fat oxidation + recovery. Plain L-carnitine-tartrate (LCLT) is more common for muscle-specific use; ALCAR if dual cognitive + muscle benefit wanted.

  • Endurance
    STANDARD TOOL

    Reduced lactate, improved fat oxidation, better recovery markers. Plain L-carnitine + carbs may be slightly more efficient mechanically; ALCAR cleaner if cognition is co-priority.

  • Bipolar / psychotic-spectrum
    CONTRAINDICATED

    without psychiatric oversight. Multiple case reports of mania/psychosis precipitation.

  • Hypothyroid (on T4/T3 replacement)
    CAUTION

    Antagonizes thyroid hormone action. Drop or expect dose titration.

  • Seizure history
    AVOID

    Reported risk of seizure exacerbation.

▸ Subjective experience (deep)
  • Onset: 30-90 min (Tmax ~3.1 h after 500 mg oral; half-life ~4.2 h).
  • Peak: 2-4 hours.
  • Character: mild, "clean" alertness without the cardiovascular/sympathetic drive of caffeine; subtle improvement in mental clarity ("less brain fog"); some users describe slightly enhanced verbal recall and word-finding. Not a felt stimulant — if you're expecting modafinil-style on-switch you'll be disappointed.
  • Variability is high: ~40-50% of users report no felt effect at standard doses; this matches the trial literature in healthy young adults.
  • Negative profile: some users (especially at >1 g) report mild restlessness, lightheadedness, or — at evening doses — vivid dreams or insomnia. A minority report headache.
  • Stacking effect: the felt effect is more reliable when stacked with citicoline or alpha-GPC (substrate + acetyl group together), and amplified by caffeine + L-theanine.
▸ Tolerance + cycling deep dive
  • Tolerance: minimal at 500 mg-1 g/day. Animal data shows neuroprotective effects do not tolerize. Mechanism is largely substrate-replenishment (ChAT, mitochondria), which doesn't downregulate the way receptor-targeting compounds do.
  • Recommended cycle (Dylan-context): 8-12 weeks on / 4 weeks off, primarily to manage TMAO accumulation, not for receptor reset. Or continuous use with quarterly TMAO checks.
  • Reset protocol: none required; 4-week washout fully clears any pseudo-tolerance and allows TMAO baseline to return.
▸ Stacking deep dive

Synergistic with

  • citicoline: ✅ Already in V4 (500 mg/day). ALCAR provides acetyl group, citicoline provides choline + cytidine → robust acetylcholine synthesis + phosphatidylcholine membrane support. Standard "ACD-style" stack.
  • alpha-gpc: ✅ Same logic as citicoline; alpha-GPC is more bioavailable choline donor but less neuroprotective evidence than citicoline. Pick one, not both, with ALCAR.
  • taurine: ✅ Mitochondrial + osmotic + GABA-A-ergic complement. Both go AM. Stack-safe.
  • l-tyrosine: ✅ Catecholamine precursor; ALCAR's dopaminergic upregulation is downstream of tyrosine availability. Useful PRN under cognitive stress.
  • agmatine: ✅ NMDA modulation + neuroprotection on a different axis. Stack-safe.
  • PQQ: ✅ Mitochondrial biogenesis (PGC-1α) + ALCAR's mitochondrial fatty-acid transport — biogenesis + utilization combination. Common longevity stack.
  • R-ALA / ALA: ✅ Often co-formulated for neuropathy/diabetic stacks. Antioxidant + ALCAR mitochondrial support.
  • DHA/omega-3: ✅ Neuronal membrane substrate — already in V4 (2 g DHA). The "ACD" stack canonically pairs ALCAR + CDP-choline + DHA.
  • Caffeine + L-theanine: ✅ Stacks well; ALCAR smooths the caffeine curve and adds cognitive substrate. Useful AM combo for Dylan post-caffeine ramp.
  • Modafinil: ✅ Compatible; ALCAR provides metabolic substrate for the increased neural activity modafinil drives. Anecdotally improves the "tail" of modafinil sessions.
  • Bromantane: ✅ Listed as part of canonical "ACD stack" in encyclopedia; bromantane increases tyrosine-hydroxylase + dopamine synthesis, ALCAR upregulates D1.

Avoid stacking with

  • Multiple high-dose AChE inhibitors (huperzine + galantamine + ALCAR + alpha-GPC + citicoline simultaneously) — risk of cholinergic excess (nausea, bradycardia, depression, "wet" feeling). ALCAR alone with one choline donor is fine.
  • Selegiline at MAO-A-inhibiting doses (>10 mg) — theoretical, low-confidence concern around tyramine + dopaminergic stacking. Low-dose selegiline (1-2.5 mg) appears safe with ALCAR per Dylan's planned V5.
  • Thyroid hormone replacement (levothyroxine, T3, NDT) — ALCAR/L-carnitine antagonizes thyroid hormone nuclear entry. If Dylan ends up on thyroid replacement post-bloodwork, drop ALCAR or expect to titrate hormone dose up.

Neutral / safe co-administration

  • All current V4 stack items: NAC, magnesium glycinate, magnesium L-threonate, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C, fish oil, creatine.
  • All planned V5 additions except thyroid replacement (TBD post-bloodwork).
▸ Drug interactions deep dive
  • Warfarin: Possible mild potentiation of anticoagulation. Evidence is weak — no high-quality reproducible signal — but case reports exist. Action: if ever on warfarin, baseline INR + recheck 1-2 weeks after starting ALCAR. Not a daily concern for Dylan.
  • Thyroid hormone (levothyroxine, liothyronine, NDT): Real interaction. L-carnitine antagonizes T3/T4 nuclear entry; therapeutic for hyperthyroid symptoms but reduces effectiveness of replacement therapy in hypothyroid patients. Requires dose titration if combined.
  • Nucleoside reverse-transcriptase inhibitors (zidovudine, stavudine, didanosine): ALCAR is actually used to treat the neuropathy these cause. Synergistic, not adverse.
  • Valproate: Carnitine deficiency is a known valproate side effect; supplementation may be indicated, but consult prescriber.
  • CYP enzymes: No significant CYP induction or inhibition reported. ALCAR does not meaningfully alter pharmacokinetics of CYP-metabolized drugs.
  • Contraceptives: No interaction reported.
▸ Pharmacogenomics

FMO3 (Flavin-Containing Monooxygenase 3) — primary relevance

  • FMO3 oxidizes gut-derived TMA → TMAO (which, paradoxically, is the cardiovascular-risk metabolite, but is odorless; TMA itself is the "rotten fish" smell).
  • >300 SNPs documented; 40+ linked to trimethylaminuria (TMAU/"fish odor syndrome"). Severe homozygous loss-of-function = clinical TMAU. Heterozygous and partial hypomorphic variants are common (~1-2% of population) and can produce subclinical odor symptoms after high carnitine/choline loads — including from ALCAR.
  • Common variants to look for in 23andMe raw data (Dylan's results due ~June 5-15):
    • rs2266782 (E158K) — common; reduced enzyme activity in heterozygotes.
    • rs2266780 (V257M) — common; variable activity.
    • rs1736557 (E308G) — less common; reduced activity.
  • Action for Dylan: when 23andMe results land, parse FMO3 status. If any common loss-of-function variants present and ALCAR is still in stack, monitor for body odor and consider switching to alternative mitochondrial supports (PQQ, CoQ10, creatine — already covered) or accept the trade-off knowing TMAO production is likely higher than baseline.

TMLHE / BBOX1 (carnitine biosynthesis)

  • Polymorphisms reduce endogenous L-carnitine synthesis (autism-associated TMLHE deficiency is rare but real). These individuals may benefit more from carnitine supplementation, though ALCAR-specific data is sparse.

SLC22A5 (OCTN2 — carnitine transporter)

  • Loss-of-function = primary carnitine deficiency (rare, severe). Heterozygous variants more common; affect tissue carnitine distribution. May modulate response to supplementation.

CHAT (choline acetyltransferase) variants

  • May modulate efficiency of ALCAR's acetyl-group → acetylcholine pathway. Limited clinical data.

CHRNA4, CHRM1 (cholinergic receptors)

  • Theoretically modulate response to cholinergic stack; clinical relevance for ALCAR specifically: low.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC Doublewood Supplements $20 / 240 caps × 500 mg = **$0.08/cap, ~$2.50/mo** at 1 cap/day High Third-party tested; clean label. Strong value pick.
OTC Jarrow Formulas (60 caps × 500 mg) $23 / 60 = **$11/mo** at 1 cap/day High Established brand; widely available iHerb/Amazon; non-GMO, gluten-free.
OTC NOW Foods (100 caps × 500 mg) $15 / 100 = **$4.50/mo** at 1 cap/day High Reliable budget pick; iHerb staple.
OTC Nootropics Depot (90 caps × 500 mg, HCl form) $20 / 90 = **$6.50/mo** at 1 cap/day High Third-party tested; published CoAs; preferred for OTC supplements per Dylan's vendor stack.
OTC Bulk powder (NOW, ND, Bulk Supplements) ~$15-25 / 100-250 g = <$1/mo at 500 mg/day High Cheapest path if you tolerate the slightly fishy taste; mix into water/juice.

Recommendation for Dylan: NOW Foods caps via iHerb (already-built supply chain) at ~$15/100 caps = ~3+ months supply. Or Nootropics Depot if he's already ordering from them for other items. Doublewood for cheapest steady-state.

Total cost estimate: $5-15/month for 500 mg/day. Negligible relative to V4/V5 budget.

Form note: ALCAR is sold as ALCAR-HCl (acid salt) or ALCAR-arginate (less common, more expensive, no clear advantage at standard doses). HCl is the workhorse form.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • Plasma TMAO (Cleveland HeartLab or equivalent) — $100-200, tells you starting point and FMO3 functional capacity.
  • Free + total carnitine, acylcarnitine panel — tells you whether you're carnitine-deficient (more upside) or replete (marginal upside).
  • Lipid panel (total chol, LDL, HDL, ApoB, Lp(a)) — baseline cardiovascular risk picture.
  • hs-CRP — baseline inflammation.
  • HbA1c, fasting glucose — diabetes status (shifts ALCAR utility profile).
  • TSH, free T3, free T4 — thyroid status (interacts with carnitine).
  • CBC, CMP — general baseline.

During use

  • Subjective tracking: energy, focus, mood, sleep quality — daily 1-10 ratings for first 4 weeks, then weekly.
  • TMAO at 3-6 months — confirm whether chronic dosing is producing concerning TMAO baseline elevation. Most informative single biomarker for ALCAR safety.
  • Lipid panel + hs-CRP at 6 months — detect any cardiovascular drift.
  • Body odor self-monitor + partner-monitor — TMAU symptoms = FMO3 saturation = high TMAO production.

Post-cycle (if cycled)

  • TMAO at end of 4-week washout — should return to baseline; if it doesn't, chronic dosing has shifted gut microbiome toward TMA-producers.
▸ Controversies / open debates Live debate
  • TMAO causality: Is TMAO causally atherogenic, or a marker of an atherogenic process (e.g., red-meat / high-saturated-fat diet = high carnitine + high choline + high LDL)? Mendelian randomization data is mixed. The mechanistic case for TMAO causality is strong (foam cells, platelet activation in vitro and in mice); the epidemiology is consistent but confounded. Consensus 2025: TMAO is at minimum a strong risk marker and probably causal at high chronic levels. Implication: even if causality is partial, chronic 30× elevation is a red flag.
  • ALCAR vs L-carnitine for TMAO production: The 2025 Krims-Davis study killed the "ALCAR is the safer form" thesis. Both produce massive TMAO bumps because gut bacteria see L-carnitine after gut hydrolysis of ALCAR.
  • Healthy young adult cognition: trial data is null/weak; user reports are mixed-to-positive; mechanistic case is plausible. Best read: real but small effect, with high inter-individual variability driven by baseline status (carnitine adequate vs deficient, choline adequate vs deficient, mitochondrial demand high vs low).
  • MAO-B inhibition claim: widely repeated in nootropics literature; primary evidence is weak. Likely a popularization of dopamine-system effects via D1 upregulation rather than MAO inhibition. Treat as low-confidence.
  • Antidepressant mechanism — epigenetic/methylation pathway: 2019 eLife paper proposed ALCAR works in nucleus accumbens via methylation of glutamate transporter genes. Mechanism is novel and only partly replicated; plausible but speculative.
  • Cognitive enhancement vs cognitive preservation: ALCAR's strongest evidence is preservation/repair (MCI, neuropathy, recovery), not enhancement of healthy young brains. The conflation in marketing copy oversells the latter.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: OPTIONAL-ADD. "Cleaner caffeine" + mitochondrial insurance for a 20yo athlete is a real but mild benefit; the only thing keeping it out of STRONG-CANDIDATE is the TMAO/cardiovascular concern, which for a 60-year time horizon is non-trivial. Cycling 8-12 on / 4 off + fiber/polyphenol diet + 6-month TMAO check makes this a reasonable optional add at $5-15/month. If 4-week trial shows no felt benefit, drop without regret.
▸ Open questions / gaps Open
  • Does TMAO elevation from supplemental carnitine produce the same cardiovascular risk trajectory as TMAO elevation from chronic high red-meat intake? Almost certainly, but no head-to-head longitudinal data exists.
  • Is there a TMAO-suppressing co-administration that fully mitigates the risk? Allicin (raw garlic) acutely suppresses gut TMA-lyase; would chronic allicin + ALCAR maintain low TMAO? Worth a self-experiment with TMAO assays.
  • Does cycling (8-12 weeks on / 4 off) actually reset TMAO to baseline, or does the gut microbiome shift persist? Unclear; would need serial TMAO measurements.
  • For Dylan specifically: does FMO3 genotype (incoming June) change the calculus? If he's homozygous wild-type, TMAO production is maximal but odor risk is low; if hypomorph, both are elevated.
  • Whether ALCAR provides any advantage over plain L-carnitine for non-cognitive endpoints (athletic, metabolic): likely no for purely peripheral effects; yes for any endpoint requiring CNS penetration.
  • Long-term (>2 year) safety data in healthy young adults: essentially none. All long-term trials are in MCI/AD/DPN populations.
▸ Sources (full, with our context)
Back to compact view